• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.27% Nasdaq Down0.19%

    Vertex Pharmaceuticals Incorporated (VRTX)

    -NasdaqGS
    140.30 Up 3.31(2.42%) Aug 4, 4:00PM EDT
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2014Dec 31, 2013Dec 31, 2012
    Total Revenue 580,415   1,211,975   1,527,042  
    Cost of Revenue60,987  130,277  279,885  
    Gross Profit 519,428   1,081,698   1,247,157  
    Operating Expenses
    Research Development855,506  882,097  765,905  
    Selling General and Administrative305,409  356,188  432,681  
    Non Recurring50,925  453,421  1,844  
    Others -   -   -  
    Total Operating Expenses -   -   -  
    Operating Income or Loss (692,412) (610,008) 46,727  
    Income from Continuing Operations
    Total Other Income/Expenses Net30,400  6,890  309  
    Earnings Before Interest And Taxes(662,012)(603,118)47,036  
    Interest Expense72,863  22,926  15,040  
    Income Before Tax(734,875)(626,044)31,996  
    Income Tax Expense6,958  (122,422)(275)
    Minority Interest4,190  242,522  (55,897)
    Net Income From Continuing Ops(741,833)(503,622)32,271  
    Non-recurring Events
    Discontinued Operations(912)(183,928)(83,406)
    Extraordinary Items -   -   -  
    Effect Of Accounting Changes -   -   -  
    Other Items -   -   -  
    Net Income (738,555) (445,028) (107,032)
    Preferred Stock And Other Adjustments -   -   -  
    Net Income Applicable To Common Shares (738,555) (445,028) (107,032)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.